Literature DB >> 23111355

Outcome of female pediatric patients diagnosed with genital tract rhabdomyosarcoma based on analysis of cases registered in SEER database between 1973 and 2006.

Charles H Kirsch1, Michael Goodman, Natia Esiashvili.   

Abstract

OBJECTIVES: We analyzed outcomes of pediatric rhabdomyosarcoma (RMS) of the female genitourinary (GU) tract using the Surveillance Epidemiology and End Result database.
MATERIALS AND METHODS: Females (0 to 19 years of age) diagnosed with RMS of GU sites between 1973 and 2006 were included in the analysis as 2 groups, 0 to 9 and 10 to 19-year-olds. They were compared for primary site distribution, stage, histology, and therapy. Kaplan-Meier method was used for survival analysis by histology, stage, and primary sites.
RESULTS: Sixty-seven cases were identified. Twenty-six cases (38.8%) had localized disease, 11 (16.2%) had regional disease, 15 (28.4%) had distant spread, and 15 (28.4%) were unstaged. The majority (85%) had embryonal RMS. Twenty-eight tumors originated in the vagina, 26 in the cervix/uterus, and 13 in other sites including vulva, labia, ovaries. Age groups did not differ with respect to race, cancer stage, histologic type, percent of cases treated surgically, and the proportion receiving radiotherapy. Vaginal RMS was predominant in the younger age group (68.4%). In the older age group, 65.5% had RMS of the cervix or uterus. This age-related prevalence of tumor sites was statistically significant (P<0.001). Survival of patients with embryonal and early-stage tumor was superior. There was no significant difference in survival by age or primary tumor site.
CONCLUSIONS: This population-based study confirmed the significance of tumor histology and stage for female GU RMS patients. Tumor sites are strongly associated with age at diagnosis.

Entities:  

Mesh:

Year:  2014        PMID: 23111355     DOI: 10.1097/COC.0b013e31826b98e4

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

1.  Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups.

Authors:  Veronique Minard-Colin; David Walterhouse; Gianni Bisogno; Helene Martelli; James Anderson; David A Rodeberg; Andrea Ferrari; Meriel Jenney; Suzanne Wolden; Gianluca De Salvo; Carola Arndt; Johannes H M Merks; Soledad Gallego; Dominique Schwob; Christine Haie-Meder; Christophe Bergeron; Michael C G Stevens; Odile Oberlin; Douglas Hawkins
Journal:  Pediatr Blood Cancer       Date:  2018-05-21       Impact factor: 3.167

2.  Prognostic Factors in Patients with Rhabdomyosarcoma Using Competing-Risks Analysis: A Study of Cases in the SEER Database.

Authors:  Didi Han; Chengzhuo Li; Xiang Li; Qiao Huang; Fengshuo Xu; Shuai Zheng; Hui Wang; Jun Lyu
Journal:  J Oncol       Date:  2020-09-17       Impact factor: 4.375

3.  Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations.

Authors:  Jennifer A Bennett; Zehra Ordulu; Robert H Young; Andre Pinto; Koen Van de Vijver; Eike Burandt; Pankhuri Wanjari; Rajeev Shah; Leanne de Kock; William D Foulkes; W Glenn McCluggage; Lauren L Ritterhouse; Esther Oliva
Journal:  Mod Pathol       Date:  2021-05-20       Impact factor: 7.842

4.  Prognostic factors for postoperative survival among patients with rhabdomyosarcoma of the limbs.

Authors:  Shihong Ren; Zhan Wang; Xin Huang; Lingling Sun; Jinxiang Shao; Zhaoming Ye
Journal:  Cancer Manag Res       Date:  2018-10-03       Impact factor: 3.989

5.  Botryoid rhabdomyosarcoma of the uterine cervix: Report case.

Authors:  R E L Qasseh; F Bouyalik; S Majidi; M Moutahir; M Benhassou; M Ennachit; M El Keroumi
Journal:  Int J Surg Case Rep       Date:  2022-07-06

6.  Uterine metastatic rhabdomyosarcoma in a scimitar-horned oryx (Oryx dammah).

Authors:  Du-Min Go; Sang-Ho Woo; Su-Hyung Lee; Soo-Whan Kwon; Dong-Hee Chung; Soong-Hee Youn; Eun Jung; Dae-Yong Kim
Journal:  J Vet Med Sci       Date:  2018-09-05       Impact factor: 1.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.